Is Neurocrine Biosciences Stock a Good Investment?
Neurocrine Biosciences Investment Advice | NBIX |
- Examine Neurocrine Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Neurocrine Biosciences' leadership team and their track record. Good management can help Neurocrine Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Neurocrine Biosciences' business and its evolving consumer preferences.
- Compare Neurocrine Biosciences' performance and market position to its competitors. Analyze how Neurocrine Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Neurocrine Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Neurocrine Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Neurocrine Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Neurocrine Biosciences is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Neurocrine Biosciences Stock
Researching Neurocrine Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The book value of Neurocrine Biosciences was now reported as 26.05. The company has Price/Earnings To Growth (PEG) ratio of 0.36. Neurocrine Biosciences last dividend was issued on the 29th of December 1995.
To determine if Neurocrine Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neurocrine Biosciences' research are outlined below:
| Neurocrine Biosciences generated a negative expected return over the last 90 days | |
| Neurocrine Biosciences has a strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 |
Neurocrine Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neurocrine Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neurocrine Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Neurocrine Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Neurocrine Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2010-10-28 | 2010-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
1997-10-31 | 1997-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
2014-04-30 | 2014-03-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2012-07-31 | 2012-06-30 | -0.03 | -0.01 | 0.02 | 66 | ||
2011-07-28 | 2011-06-30 | 0.06 | 0.04 | -0.02 | 33 | ||
2013-10-29 | 2013-09-30 | -0.2 | -0.17 | 0.03 | 15 | ||
1998-11-02 | 1998-09-30 | -0.19 | -0.22 | -0.03 | 15 | ||
1998-08-04 | 1998-06-30 | -0.17 | -0.14 | 0.03 | 17 |
Neurocrine Biosciences Target Price Consensus
Neurocrine target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Neurocrine Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 24 | Strong Buy |
Most Neurocrine analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Neurocrine stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Neurocrine Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationNeurocrine Biosciences Target Price Projection
Neurocrine Biosciences' current and average target prices are 115.02 and 167.67, respectively. The current price of Neurocrine Biosciences is the price at which Neurocrine Biosciences is currently trading. On the other hand, Neurocrine Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Neurocrine Biosciences Market Quote on 17th of February 2025
Target Price
Analyst Consensus On Neurocrine Biosciences Target Price
Neurocrine Biosciences Analyst Ratings
Neurocrine Biosciences' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Neurocrine Biosciences stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Neurocrine Biosciences' financials, market performance, and future outlook by experienced professionals. Neurocrine Biosciences' historical ratings below, therefore, can serve as a valuable tool for investors.Know Neurocrine Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neurocrine Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neurocrine Biosciences backward and forwards among themselves. Neurocrine Biosciences' institutional investor refers to the entity that pools money to purchase Neurocrine Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wellington Management Company Llp | 2024-12-31 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.3 M | Deerfield Management Co | 2024-09-30 | 1.3 M | Goldman Sachs Group Inc | 2024-09-30 | 1 M | Brown Advisory Holdings Inc | 2024-09-30 | 942.1 K | Rock Springs Capital Management Lp | 2024-09-30 | 939 K | Dsm Capital Partners Llc | 2024-12-31 | 932.6 K | Braidwell Lp | 2024-12-31 | 901.8 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 894.2 K | Blackrock Inc | 2024-09-30 | 14.3 M | Vanguard Group Inc | 2024-12-31 | 10.1 M |
Neurocrine Biosciences' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 11.47 B.Market Cap |
|
Neurocrine Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.18 | 0.19 | |
| Return On Assets | 0.09 | 0.10 | |
| Return On Equity | 0.13 | 0.14 |
Determining Neurocrine Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Neurocrine Biosciences is a good buy. For example, gross profit margin measures Neurocrine Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neurocrine Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Neurocrine Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Neurocrine Biosciences. Check Neurocrine Biosciences' Beneish M Score to see the likelihood of Neurocrine Biosciences' management manipulating its earnings.
Evaluate Neurocrine Biosciences' management efficiency
Neurocrine Biosciences has return on total asset (ROA) of 0.1046 % which means that it generated a profit of $0.1046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1416 %, meaning that it created $0.1416 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.1 in 2025. Return On Capital Employed is likely to rise to 0.19 in 2025. At this time, Neurocrine Biosciences' Return On Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.67 in 2025, whereas Intangibles To Total Assets are likely to drop 0.01 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 25.79 | 27.08 | |
| Tangible Book Value Per Share | 25.43 | 26.70 | |
| Enterprise Value Over EBITDA | 22.83 | 23.97 | |
| Price Book Value Ratio | 5.29 | 6.06 | |
| Enterprise Value Multiple | 22.83 | 23.97 | |
| Price Fair Value | 5.29 | 6.06 | |
| Enterprise Value | 6.2 B | 6.6 B |
The operational strategies employed by Neurocrine Biosciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 0.334 |
Basic technical analysis of Neurocrine Stock
As of the 17th of February 2025, Neurocrine Biosciences secures the Standard Deviation of 2.74, risk adjusted performance of (0.02), and Mean Deviation of 1.41. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurocrine Biosciences, as well as the relationship between them.Neurocrine Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neurocrine Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neurocrine Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neurocrine Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neurocrine Biosciences' Outstanding Corporate Bonds
Neurocrine Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neurocrine Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neurocrine bonds can be classified according to their maturity, which is the date when Neurocrine Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US64128XAE04 Corp BondUS64128XAE04 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Neurocrine Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Neurocrine Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 1.41 | |||
| Coefficient Of Variation | (2,915) | |||
| Standard Deviation | 2.74 | |||
| Variance | 7.53 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.10) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 23.54 | |||
| Value At Risk | (2.46) | |||
| Potential Upside | 2.19 | |||
| Skewness | (4.71) | |||
| Kurtosis | 31.66 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 1.41 | |||
| Coefficient Of Variation | (2,915) | |||
| Standard Deviation | 2.74 | |||
| Variance | 7.53 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.10) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 23.54 | |||
| Value At Risk | (2.46) | |||
| Potential Upside | 2.19 | |||
| Skewness | (4.71) | |||
| Kurtosis | 31.66 |
Consider Neurocrine Biosciences' intraday indicators
Neurocrine Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neurocrine Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0272 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 115.38 | |||
| Day Typical Price | 115.26 | |||
| Market Facilitation Index | 3.18 | |||
| Price Action Indicator | (0.36) | |||
| Relative Strength Index | 31.6 |
Neurocrine Biosciences Corporate Filings
F4 | 14th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 10th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 6th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 5th of February 2025 Other Reports | ViewVerify |
Neurocrine Stock media impact
Far too much social signal, news, headlines, and media speculation about Neurocrine Biosciences that are available to investors today. That information is available publicly through Neurocrine media outlets and privately through word of mouth or via Neurocrine internal channels. However, regardless of the origin, that massive amount of Neurocrine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neurocrine Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neurocrine Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neurocrine Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neurocrine Biosciences alpha.
Neurocrine Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Neurocrine Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neurocrine Biosciences Historical Investor Sentiment
Investor biases related to Neurocrine Biosciences' public news can be used to forecast risks associated with an investment in Neurocrine. The trend in average sentiment can be used to explain how an investor holding Neurocrine can time the market purely based on public headlines and social activities around Neurocrine Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neurocrine Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neurocrine Biosciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Neurocrine Biosciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Neurocrine Biosciences.
Neurocrine Biosciences Maximum Pain Price Across May 16th 2025 Option Contracts
Neurocrine Biosciences' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Neurocrine Biosciences close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Neurocrine Biosciences' options.
Neurocrine Biosciences Corporate Management
| Julie Cooke | Chief People Officer | Profile | |
| Matthew Abernethy | Chief Officer | Profile | |
| Eric Benevich | Chief Commercial Officer | Profile | |
| Darin Lippoldt | Chief Legal Officer | Profile | |
| Jude Onyia | Chief Officer | Profile | |
| Dimitri Grigoriadis | Chief Research Officer | Profile | |
| Kyle Gano | Chief Business Development Officer | Profile |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.